Exhibit 10.1


 


UNSECURED PROMISSORY NOTE


 


	$1,600,000	Dated as of May 10, 2016


 


This Unsecured Promissory Note (this “Note”)
is dated as of May 10, 2016, by and between Vaccinogen, Inc., a Maryland corporation (“Vaccinogen”) and
KLP Enterprises, LLC, a limited liability company formed under the laws of Delaware (the “Lender”).


 


Agreement


 


FOR VALUE RECEIVED,
the undersigned, (“Vaccinogen”), hereby promises to pay to the order of the Lender, the principal sum
of One Million, Six Hundred Thousand Dollars ($1,600,000) (the “Principal Amount”) in lawful money of the United
States of America, and together with interest thereon at the rate hereinafter specified and any and all other sums which may be
due and owing hereunder to the Lender, which shall be paid at the address of the Lender below, in accordance with the terms contained
herein.


 


1.          Interest.
Vaccinogen shall pay interest from the date of this Unsecured Promissory Note (this “Note”) on the Principal
Amount outstanding from time to time at a rate per annum equal to nine percent (9%). The interest shall be due and payable on the
Maturity Date (hereinafter defined).


 


2.          Calculation
of Interest. Interest on the Principal Amount of this Note shall be calculated on the basis of a 360 day per year factor applied
to the actual days on which there exists an unpaid principal balance due under this Note.


 


3.          Maturity.
The entire Principal Amount and all accrued interest shall become fully due and payable on June 30, 2016 (the “Maturity
Date”); provided that, at any time before the Maturity Date, the Lender may elect to convert part or all of the
outstanding principal and any interest due and payable under the Promissory Note at such time into shares of Vaccinogen’s
common stock, par value $0.0001 per share (the “Common Stock”), at a rate of $2.00 per share by providing written
notice to Vaccinogen of such election (the “Conversion Right”). Upon receipt of such written notice, Vaccinogen
shall issue the corresponding whole number of shares to the Lender within a commercially reasonable period of time. For the avoidance
of doubt, an issuance of the Common Stock pursuant to this paragraph shall not constitute a default under this Note.


 


4.          Prepayment.
Vaccinogen may prepay this Note, together with all then accrued interest, in whole or in part at any time, or from time to time,
without penalty or additional interest; provided that Vaccinogen must provide five days’ notice (the “Five
Day Notice”) of such prepayment to the Lender and Lender shall have the right (but not the obligation) to exercise the
Lender’s Conversion Right prior to the expiration of such five day period. If Lender does not exercise such Conversion Right
prior to the expiration of such five day period, Vaccinogen shall prepay this Note in the manner and to the extent provided in
such Five Day Notice within three business days following the expiration of the period provided for in the Five Day Notice. Any
amounts prepaid hereunder shall be applied as provided in Section 5 below.


 




     


     


    

 


5.          Payments.
Except as otherwise stated in Paragraph 3 hereof, all payments made hereunder shall be in lawful money of the United States of
America. All payments and prepayments shall be applied first to costs of collection, next, to accrued interest, and thereafter
to principal.


 


6.          Default
and Remedies. The following shall be a default under this Note and shall entitle the Lender to all of the rights and remedies
specified herein or otherwise available under applicable law or in equity: (i) any failure to make any payment due under this Note
when due or upon the failure to comply with any other terms and provisions of this Note, if such failures remain uncured for a
period of ten (10) business days; (ii) a petition for relief in a bankruptcy court is filed by Vaccinogen or Vaccinogen applies
for, consents to or acquiesces in the appointment of a trustee, custodian or receiver for Vaccinogen or any of its assets or property
or make a general assignment for the benefit of its creditors or, in the absence of such application, consent or acquiescence,
a trustee, custodian or receiver is appointed for Vaccinogen or for a substantial part of its assets or property and is not discharged
within thirty (30) days thereafter; (iii) any bankruptcy, reorganization, debt arrangement or other proceeding or case under any
bankruptcy or insolvency law or any dissolution or liquidation proceeding is instituted against Vaccinogen and if instituted against
Vaccinogen is consented to or acquiesced in by Vaccinogen or remains undismissed for sixty (60) days thereafter; or (iv) Vaccinogen
takes any action to authorize any of the actions described in subsection (ii) or (iii). Vaccinogen hereby waives presentment, demand
for payment, notice of dishonor, notice of protest, and protest, and all other notices or demands in connection with the delivery,
acceptance and performance of this Note.


 


7.          Governing
Law. This Note and all actions arising out of or in connection with this Note shall be governed by and construed in accordance
with the laws of the State of Maryland.


 


8.          No
Waiver. The delay or failure of the Lender to exercise its rights hereunder shall not be deemed a waiver thereof. No waiver
of any rights of the Lender shall be effective unless in writing and signed by the Lender and any waiver of any right shall not
apply to any other right or to such right in any subsequent event or circumstance not specifically included in such waiver.


 


9.          Successors
and Assigns. This Note shall not be assignable by the Lender without the prior written consent of Vaccinogen. This Note shall
be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. For the avoidance
of doubt, the right to receive the Common Stock described in Paragraph 3 above shall not be assignable by the Lender without the
prior written consent of Vaccinogen.


 




    	 	2	 



     


    

 


10.         No
Senior Debt. Vaccinogen does not currently have any indebtedness for borrowed money or any obligations evidenced by notes or
debentures or similar instruments (collectively, “Debt”), except (i) indebtedness
owed to Organon Teknika Corporation (now Merck) in the amount of $3,000,000 (plus accrued interest calculated from October
31, 2007 based on a simple annual interest rate based on the prime lending rate in effect on the anniversary of October 31, 2007)
pursuant to that certain Letter Agreement, dated October 31, 2007, among Intracel Holdings Corporation, Intracel Acquisition Holdings
Company LLC, Organon Biosciences International B.V., and Organon Teknika Corp (the “Merck Debt”) and (ii) indebtedness
owed to Dolphin Offshore Partners, LP (“Dolphin”) in the amount of $1,600,000 (plus accrued thereon from March
31, 2016) pursuant to that certain Unsecured Promissory Note, effective as of March 31, 2016, issued by Vaccinogen in Favor of
Dolphin (the “Dolphin Debt”). The Merck Debt is due one (1) year after the first marketing approval of OncoVax
by the United States Food and Drug Administration or the European Medicines Agency, whichever is first, in annual payments of $1,000,000
(plus accrued interest) until collection of the entire outstanding amount (subject to certain acceleration provisions). The Dolphin
Debt matures on June 30, 2016. From the date hereof and until the date that this Note is paid in full, Vaccinogen shall not incur,
create or assume any additional Debt, except: (a) Debt existing or arising under this Note and any refinancing thereof; and (b)
Debt that is subordinate to the prior payment in full of the obligations evidenced by this
Note.


 


11.         Separate
Counsel. Each of the parties hereto acknowledges that (i) he/she/it has read this Note in its entirety and understands all
of its terms and conditions, (ii) he/she/it has had the opportunity to consult with any individuals of their choice regarding their
agreement to the provisions contained herein, including legal counsel of their choice, and any decision not to was theirs alone,
and (iii) he/she/it is entering into this Note of their own free will, without coercion from any source. Each of Lender and Vaccinogen
acknowledges and agrees that Venable LLP is representing Vaccinogen in connection with this Note, and does not represent Lender.


 


12.         Subscription
Agreement. The Lender acknowledges and agrees that Vaccinogen’s obligation to issue the Common Stock pursuant to Paragraph
3 above is conditioned upon Vaccinogen and the Lender entering into a mutually agreed subscription agreement prior to such issuance,
which agreement will be substantially in the form set forth in Annex A hereto.


 


13.         Notices.
Any notices or other communication required hereunder shall be deemed properly given if delivered in person or if mailed by registered
or certified mail, postage prepaid, return receipt requested to the parties at the following addresses:


 


if to Vaccinogen,
to:


 


Vaccinogen, Inc.


949 Fell Street


2nd Floor


Baltimore, MD 21231


Attn: President


 


with a copy to:


 


Venable LLP


750 E. Pratt Street


Baltimore, Maryland 21202


Attn: Eric R. Smith, Esq.


 




    	 	3	 



     


    

 


if to the Lender:


 


KLP Enterprises, LLC


35 Windsor Road


North Haven, CT 06473


Attn: Andrew Wingate


 


[Signatures
on following page]


 




    	 	4	 



     


    

 


IN WITNESS WHEREOF, Vaccinogen has
caused this Note to be executed on its behalf by its duly authorized officer as of May 10, 2016.


 


	VACCINOGEN, INC.	 
	 	 
	By:	 	 
	Name: Andrew L. Tussing	 
	Title: Chairman and Chief Executive Officer	 
	 	 
	AGREED TO AND ACKNOWLEDGED	 
	 	 
	KLP Enterprises, LLC	 
	 	 
	By:	 	 
	Name:  Andrew Wingate	 
	Title:  Manager	 


 




    	 	5	 



     


    

 


ANNEX A


 


Subscription Agreement


 


THE SECURITIES HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER
RESTRICTIONS ON THE TRANSFERABILITY OF THE SECURITIES DESCRIBED HEREIN.


 


THE PURCHASE OF THE
SECURITIES INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN BEAR THE RISK OF THE LOSS OF THEIR ENTIRE
INVESTMENT.


 


Ladies and Gentlemen:


 


The undersigned understands
that VACCINOGEN, INC., a corporation organized under the laws of Maryland (the “Company”), is offering shares
of its common stock, par value $0.0001 per share in a private placement. The undersigned further understands that the offering
is being made without registration of the Securities under the Securities Act of 1933, as amended (the “Securities Act”),
or any securities law of any state of the United States or of any other jurisdiction, and is being made only to “Accredited
Investors” (as defined in Rule 501 of Regulation D under the Securities Act).


 


1.          Subscription.
Subject to the terms and conditions of this Subscription Agreement (this “Subscription Agreement”), on the date of
the Closing referred to in Section 3 hereof, the undersigned shall purchase from the Company and the Company shall sell
to the undersigned [ ] shares of common stock, par value $0.0001 per share (the “Securities”), for the aggregate purchase
price of [$ ], at [$ ] per share.


 


2.          Acceptance
of Subscription and Issuance of Securities. Notwithstanding anything in this Subscription Agreement to the contrary, the Company
shall have no obligation to issue any of the Securities to any person who is a resident of a jurisdiction in which the issuance
of the Securities to such person would constitute a violation of the securities, “blue sky” or other similar laws
of such jurisdiction (collectively referred to as the “State Securities Laws”).


 


3.          The
Closing. The closing of the purchase and sale of the Securities (the “Closing”) shall take place at the
offices of the Company on the date the Company countersigns this Subscription Agreement, or at such other time and place as the
Company may designate.


 




    	 	6	 



     


    

 


4.          Payment
for Securities. Consideration for the issuance of the Securities having already been received by the Company, the Company
shall deliver certificates or other appropriate evidence of the Securities to the undersigned at the Closing bearing an appropriate
legend referring to the fact that the Securities were sold in reliance upon an exemption from registration under the Securities
Act.


 


5.          Representations
and Warranties of the Company. As of the Closing, the Company represents and warrants that the Company is duly formed and
validly existing under the laws of Maryland, with full power and authority to conduct its business as it is currently being conducted
and to own its assets; and has secured any other authorizations, approvals, permits and orders required by law for the conduct
by the Company of its business as it is currently being conducted.


 


6.          Representations
and Warranties of the Undersigned. The undersigned hereby represents and warrants to and covenants with the Company that:


 


(a)          General.


 


(i)          The
undersigned has all requisite authority to receive the Securities, enter into this Subscription Agreement and to perform all the
obligations required to be performed by the undersigned hereunder, and such purchase will not contravene any law, rule or regulation
binding on the undersigned or any investment guideline or restriction applicable to the undersigned.


 


(ii)         The
undersigned is a resident of the state set forth on the signature page hereto and is not acquiring the Securities as a nominee
or agent or otherwise for any other person.


 


(iii)        The
undersigned will comply with all applicable laws and regulations in effect in any jurisdiction in which the undersigned purchases
or sells the Securities and obtain any consent, approval or permission required for such purchases or sales under the laws and
regulations of any jurisdiction to which the undersigned is subject or in which the undersigned makes such purchases or sales,
and the Company shall have no responsibility therefor.


 


(b)          Information
Concerning the Company.


 


(i)          The
undersigned has been given the opportunity to ask questions and receive answers concerning the terms and conditions of the issuance
of the Securities. The undersigned has been given the opportunity to obtain material and relevant information from the Company
enabling it to make an informed investment decision. All data that the undersigned has requested has been furnished to it. The
undersigned is aware of and has access to the Company’s public filings with the Securities and Exchange Commission (the
“Public Filings”).


 


(ii)         The
undersigned understands and accepts that the purchase of the Securities involves various risks, including the risks outlined in
this Subscription Agreement and the Public Filings. The undersigned represents that it is able to bear any loss associated with
an investment in the Securities.


 




    	 	7	 



     


    

 


(iii)        The
undersigned confirms that it is not relying on any communication (written or oral) of the Company or any of its affiliates, as
investment advice or as a recommendation to purchase the Securities. It is understood that information and explanations related
to the terms and conditions of the Securities provided by the Company or any of its affiliates shall not be considered investment
advice or a recommendation to purchase the Securities, and that neither the Company nor any of its affiliates is acting or has
acted as an advisor to the undersigned in deciding to invest in the Securities. The undersigned acknowledges that neither the
Company nor any of its affiliates has made any representation regarding the proper characterization of the Securities for purposes
of determining the undersigned’s authority to invest in the Securities.


 


(iv)        The
undersigned is familiar with the business and financial condition and operations of the Company. The undersigned has had access
to such information concerning the Company and the Securities as it deems necessary to enable it to make an informed investment
decision concerning the purchase of the Securities.


 


(v)         The
undersigned understands that, unless the undersigned notifies the Company in writing to the contrary at or before the Closing,
each of the undersigned’s representations and warranties contained in this Subscription Agreement will be deemed to have
been reaffirmed and confirmed as of the Closing, taking into account all information received by the undersigned.


 


(vi)        The
undersigned understands that no federal or state agency has passed upon the merits or risks of an investment in the Securities
or made any finding or determination concerning the fairness or advisability of this investment.


 


(c)          Non-reliance.


 


(i)          The
undersigned represents that it is not relying on (and will not at any time rely on) any communication (written or oral) of the
Company, as investment advice or as a recommendation to purchase the Securities, it being understood that information and explanations
related to the terms and conditions of the Securities shall not be considered investment advice or a recommendation to purchase
the Securities.


 


(ii)         The
undersigned confirms that the Company has not (A) given any guarantee or representation as to the potential success, return, effect
or benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment in the Securities or (B) made any
representation to the undersigned regarding the legality of an investment in the Securities under applicable legal investment or
similar laws or regulations. In deciding to purchase the Securities, the undersigned is not relying on the advice or recommendations
of the Company and the undersigned has made its own independent decision that the investment in the Securities is suitable and
appropriate for the undersigned.


 




    	 	8	 



     


    

 


(d)          Status
of Undersigned.


 


(i)          The
undersigned has such knowledge, skill and experience in business, financial and investment matters that the undersigned is capable
of evaluating the merits and risks of an investment in the Securities. With the assistance of the undersigned’s own professional
advisors, to the extent that the undersigned has deemed appropriate, the undersigned has made its own legal, tax, accounting and
financial evaluation of the merits and risks of an investment in the Securities and the consequences of this Subscription Agreement.
The undersigned has considered the suitability of the Securities as an investment in light of its own circumstances and financial
condition and the undersigned is able to bear the risks associated with an investment in the Securities and its authority to invest
in the Securities.


 


(ii)         The
undersigned is an “accredited investor” as defined in Rule 501(a) under the Securities Act. The undersigned agrees
to furnish any additional information requested by the Company or any of its affiliates to assure compliance with applicable U.S.
federal and state securities laws in connection with the purchase and sale of the Securities. The undersigned acknowledges that
the undersigned has completed the Investor Questionnaire contained in Appendix A (the “Questionnaire”)
and that the information and representations contained therein is complete and accurate as of the date thereof and is hereby affirmed
as of the date hereof and as of the Closing. Any information that has been furnished or that will be furnished by the undersigned
to evidence its status as an accredited investor is accurate and complete, and does not contain any misrepresentation or material
omission.


 


(e)          Restrictions
on Transfer or Sale of Securities.


 


(i)          The
undersigned is acquiring the Securities solely for the undersigned’s own beneficial account, for investment purposes, and
not with a view to, or for resale in connection with, any distribution of the Securities. The undersigned understands that the
Securities have not been registered under the Securities Act or any State Securities Laws by reason of specific exemptions under
the provisions thereof which depend in part upon the investment intent of the undersigned and of the other representations made
by the undersigned in this Subscription Agreement and the Questionnaire. The undersigned understands that the Company is relying
upon the representations and agreements contained in this Subscription Agreement and the Questionnaire (and any supplemental information)
for the purpose of determining whether this transaction meets the requirements for such exemptions.


 


(ii)         The
undersigned understands that the Securities are “restricted securities” under applicable federal securities laws and
that the Securities Act and the rules of the U.S. Securities and Exchange Commission (the “Commission”) provide
in substance that the undersigned may dispose of the Securities only pursuant to an effective registration statement under the
Securities Act or an exemption therefrom, and the undersigned understands that the Company has no obligation or intention to register
any of the Securities, or to take action so as to permit sales pursuant to the Securities Act (including Rule 144 thereunder).
Consequently, the undersigned understands that the undersigned must bear the economic risks of the investment in the Securities
for an indefinite period of time.


 




    	 	9	 



     


    

 


(iii)        The
undersigned agrees: (A) that the undersigned will not sell, assign, pledge, give, transfer or otherwise dispose of the Securities
or any interest therein, or make any offer or attempt to do any of the foregoing, except pursuant to a registration of the Securities
under the Securities Act and all applicable State Securities Laws, or in a transaction which is exempt from the registration provisions
of the Securities Act and all applicable State Securities Laws; (B) that the certificates or book entries representing the Securities
will bear a legend making reference to the foregoing restrictions; and (C) that the Company and its affiliates shall not be required
to give effect to any purported transfer of such Securities except upon compliance with the foregoing restrictions.


 


(iv)        The
undersigned acknowledges that neither the Company nor any other person offered to sell the Securities to it by means of any form
of general solicitation or advertising, including but not limited to: (A) any advertisement, article, notice or other communication
published in any newspaper, magazine or similar media or broadcast over television or radio or (B) any seminar or meeting whose
attendees were invited by any general solicitation or general advertising.


 


7.          Conditions
to Obligations of the Undersigned and the Company. The obligations of the undersigned to purchase and pay for the Securities
specified in Section 1 and of the Company to sell the Securities are subject to the satisfaction at or prior to the Closing
of the following conditions precedent: the representations and warranties of the Company contained in Section 5 hereof
and of the undersigned contained in Section 6 hereof shall be true and correct as of the Closing in all respects with the
same effect as though such representations and warranties had been made as of the Closing.


 


8.          Obligations
Irrevocable. The obligations of the undersigned shall be irrevocable.


 


9.          Legend.
Any certificates representing the Securities sold pursuant to this Subscription Agreement will be imprinted with a legend in substantially
the following form:


 


“THE SECURITIES
EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED
EXCEPT (1) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE STATE SECURITIES LAWS AND THE SECURITIES LAWS OF OTHER
JURISDICTIONS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE
LAWS.”


 




    	 	10	 



     


    

 


10.         Waiver,
Amendment. Neither this Subscription Agreement nor any provisions hereof shall be modified, changed, discharged or terminated
except by an instrument in writing, signed by the party against whom any waiver, change, discharge or termination is sought.


 


11.         Assignability.
Neither this Subscription Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall
be assignable by either the Company or the undersigned without the prior written consent of the other party.


 


12.         Waiver
of Jury Trial. THE UNDERSIGNED IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY LEGAL PROCEEDING
ARISING OUT OF THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT. Each party
to this Subscription Agreement certifies and acknowledges that (a) no representatives of any other party has represented, expressly
or otherwise, that such other party would not seek to enforce the foregoing waiver in the event of a legal action; (b) such party
has considered the implications of this waiver; (c) such party makes this waiver voluntarily; and (d) such party has been induced
to enter into this Subscription Agreement by, among other things, the mutual waivers and certifications in this section.


 


13.         Submission
to Jurisdiction. With respect to any suit, action or proceeding relating to any offers, purchases or sales of the Securities
by the undersigned (“Proceedings”), the undersigned irrevocably submits to the jurisdiction of the federal
or state courts located in the State of Maryland, which submission shall be exclusive unless none of such courts has lawful jurisdiction
over such Proceedings.


 


14.         Governing
Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of Maryland.


 


15.         Section
and Other Headings. The section and other headings contained in this Subscription Agreement are for reference purposes only
and shall not affect the meaning or interpretation of this Subscription Agreement.


 


16.         Counterparts.
This Subscription Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall
be deemed to be an original and all of which together shall be deemed to be one and the same agreement.


 


17.         Notices.
All notices and other communications provided for herein shall be in writing and shall be deemed to have been duly given if delivered
personally or sent by registered or certified mail, return receipt requested, postage prepaid to the following addresses (or such
other address as either party shall have specified by notice in writing to the other):


 




    	 	11	 



     


    

 


	If to the Company:	
        Vaccinogen, Inc.

         

        949 Fell Street

         

        Baltimore, MD 21231

         

        Attention: Chief Executive
        Officer

         

	with a copy to:	
        Venable LLP

         

        750 E. Pratt Street,
        Suite 900

         

        Baltimore, MD 21202

         

        Attention:   Eric
        R. Smith, Esq.

         

	If to the Purchaser:	
        KLP Enterprises, LLC

         

        35 Windsor Road

         

        North Haven, CT 06473

         

        Attention:  Andrew
        Wingate



 


18.         Binding
Effect. The provisions of this Subscription Agreement shall be binding upon and accrue to the benefit of the parties hereto
and their respective heirs, legal representatives, successors and assigns.


 


19.         Survival.
All representations, warranties and covenants contained in this Subscription Agreement shall survive (i) the acceptance of the
subscription by the Company and the Closing, and (ii) the death, disability, or dissolution of the undersigned.


 


20.         Notification
of Changes. The undersigned hereby covenants and agrees to notify the Company upon the occurrence of any event prior to the
closing of the purchase of the Securities pursuant to this Subscription Agreement, which would cause any representation, warranty,
or covenant of the undersigned contained in this Subscription Agreement to be false or incorrect.


 


21.         Severability.
If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality
or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term
or provision in any other jurisdiction.


 


[SIGNATURE PAGE FOLLOWS]


 




    	 	12	 



     


    

 


 


IN WITNESS WHEREOF,
the undersigned has executed this Subscription Agreement this ____ of ______________________, 2016


 


	 	KLP Enterprises, LLC:
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 


 


The offer to purchase
Securities as set forth above is confirmed and accepted by the Company as to [   ]
shares of common stock.


 


	 	Vaccinogen, Inc.
	 	 
	 	By:	 
	 	Name:	Andrew L. Tussing
	 	Title:	Chief Executive Officer


 




    	 	13	 



     


    

 


APPENDIX A


 


INVESTOR QUESTIONNAIRE


 


This Questionnaire
is being distributed to the undersigned investor (the “Investor”) by Vaccinogen, Inc., a Maryland corporation (the
“Issuer”) in connection with the Subscription Agreement of the Investor to which this Questionnaire is a part (the
“Subscription Agreement”), to enable the Issuer to determine whether the Investor is qualified to invest in the Securities
(as defined in the Subscription Agreement). To be qualified to invest in the Securities, the Investor must be an “Accredited
Investor” (as that term is defined in Rule 501(a) of Regulation D promulgated under Section 4(a)(2) of the Securities Act
of 1933, as amended (the “Securities Act”)).


 


The Issuer will rely
upon the accuracy and completeness of the information provided in this Questionnaire in establishing that the issuance of the Securities
is exempt from the registration requirements of the Securities Act.


 


ACCORDINGLY, THE
INVESTOR IS OBLIGATED TO READ THIS QUESTIONNAIRE CAREFULLY AND TO ANSWER THE ITEMS CONTAINED HEREIN COMPLETELY AND ACCURATELY.


 


ALL INFORMATION CONTAINED
IN THIS QUESTIONNAIRE WILL BE TREATED CONFIDENTIALLY. However, the Investor understands and agrees that the Issuer may present,
upon giving prior notice to the Investor, this Questionnaire to such parties as the Issuer deems appropriate if called upon to
establish that the issuance of the Securities (i) is exempt from the registration requirements of the Securities Act or (ii) meets
the requirements of applicable state securities laws; provided, however, that the Issuer need not give prior notice to the
Investor of its presentation of this Questionnaire to the Issuer’s regularly employed legal, accounting and financial advisors.


 


The Investor understands
that this Questionnaire is merely a request for information and is not an offer to sell, a solicitation of an offer to buy, or
a sale of the Securities. The Investor also understands that the Investor may be required to furnish additional information.


 


PLEASE NOTE THE FOLLOWING
INSTRUCTIONS BEFORE COMPLETING THIS INVESTOR QUESTIONNAIRE.


 


Unless instructed otherwise,
the Investor should answer each question on the Questionnaire. If the answer to a particular question is “None” or
“Not Applicable,” please so state. If the Questionnaire does not provide sufficient space to answer a question, please
attach a separate schedule to your executed Questionnaire that indicates which question is being answered thereon. Persons having
questions concerning any of the information requested in this Questionnaire should consult with their purchaser representative
or representatives, lawyer, accountant or broker or may call Amanda C. E. Knab, Esq., Venable LLP, at 410.244.6514.


 




    	 	14	 



     


    

 


1. General Information


 


Name of Entity: KLP
Enterprises LLC


 


Address of Principal Office: 35 Windsor
Road, North Haven, CT 06473


 


Type of Organization:
Limited liability company


 


Date and State of Organization:
●


 


 2. Accredited
Investor Status


 


To be qualified to
invest in the Securities, the Investor must be an Accredited Investor.


 


Please check the appropriate
description which applies to you.


 


(a) ____________ A
bank, as defined in Section 3(a)(2) of the Securities Act or any savings and loan association or other institution as defined in
Section 3(a)(5)(A) of the Securities Act, whether acting in an individual or a fiduciary capacity.


 


(b) ____________ A
broker or dealer registered under Section 15 of the Securities Exchange Act of 1934, as amended.


 


(c) ____________ An
insurance company, as defined in Section 2(13) of the Securities Act.


 


(d) ____________ An
investment company registered under the Investment Company Act of 1940 or a business development company, as defined in Section
2(a)(48) of that act.


 


(e) ____________ A
Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business
Investment Act of 1958.


 


(f) ____________ A
plan established and maintained by a state, its political subdivisions or any agency or instrumentality of a state or its political
subdivisions for the benefit of its employees, if the plan has total assets in excess of $5 million.


 




    	 	15	 



     


    

 


(g) ____________ An
employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974, if the investment decision
is being made by a plan fiduciary, as defined in Section 3(21) of such act, and the plan fiduciary is either a bank, a savings
and loan association, an insurance company, or a registered investment adviser, or if the employee benefit plan has total assets
in excess of $5 million or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors.


 


(h) ____________ A
private business development company, as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.


 


(i) ____________ A
corporation, Massachusetts or similar business trust, or partnership, or an organization described in Section 501(c)(3) of the
Internal Revenue Code of 1986, as amended, that was not formed for the specific purpose of acquiring the Securities, and that has
total assets in excess of $5 million.


 


(j) _____________ A
trust with total assets in excess of $5 million not formed for the specific purpose of acquiring the Securities, whose purchase
is directed by a sophisticated person as described in Rule 506(b)(2)(ii) under the Securities Act.


 


(k) _____________ An
entity in which all of the equity owners are accredited investors and meet the criteria listed in Part I, Item 2 of this Questionnaire.


 


3. Representations


 


The undersigned entity
represents that:


 


(a) The entity understands
that the Issuer will rely upon the completeness and accuracy of the entity’s responses to the questions in this Questionnaire
in establishing that the contemplated transactions are exempt from the Securities Act, and hereby affirms that all such responses
are accurate and complete. The entity will notify the Issuer immediately of any changes in any of such information occurring prior
to the acceptance of its subscription.


 


(b) The entity is not
a retirement plan, employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”) or Section 4975 of the IRS Code (or an entity whose assets are deemed to include assets of those plans under
the Department of Labor’s “plan asset regulation”), a corporate pension and profit-sharing plan, a “simplified
employee pension plan,” a “Keogh” plan, an Individual Retirement Account,  or retirement or employee benefit
plan not subject to ERISA.


 


[SIGNATURE PAGE FOLLOWS]


 




    	 	16	 



     


    

 


	KLP Enterprises LLC	 
	 	 
	By:	 	 
	 	 
	Name: ●	 
	 	 
	Title: ●	 
	 	 
	Date: